Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QAW039 dose-ranging trial in allergic asthma inadequately controlled on inhaled corticosteroids
NL-OMON37185Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fevipiprant in allergic asthma and asthma (3 arms), sponsored by Novartis. Primary endpoint: Trough FEV1 at week 12. Started Jul 2012; status: active, not recruiting.
02
Drugs
fevipiprant
03
Conditions
allergic asthmaasthma
Beyond the preview
Go deeper on NL-OMON37185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37185.